15 results about "Intestinal motility" patented technology

The application discloses a postoperative gastrointestinal motility closed-loop management system and belongs to the technical field of postoperative gastrointestinal motility nursing, which comprises the following: a wireless distributed sensing node attached to key acupoints on the abdomen for collecting borborygmus, gastrointestinal slow wave, abdominal tension and IMU motion posture; an edge computing control terminal running an adaptive multi-modal fusion algorithm, calculating a gastrointestinal motility index MI(t) by dynamically updating weights through Kalman filtering or variational Bayesian inference; a two-stage safety execution module containing software logic fusing (stopping when the algorithm judges an abnormality) and hardware physical fusing (MOSFET relay forced power-off); and a cloud monitoring platform supporting remote visual monitoring, data tracing, OTA upgrading and adopting AES-256 hardware encryption; the system realizes a four-layer closed-loop architecture from sensing, decision-making, execution and monitoring. The application significantly shortens the postoperative gastrointestinal function recovery time and reduces the incidence of complications through non-invasive multi-modal monitoring and closed-loop feedback.

This invention provides the application of Liu Mo Tang freeze-dried powder in the preparation of products regulating intestinal flora imbalance, belonging to the field of biomedical technology. The Liu Mo Tang freeze-dried powder provided by this invention effectively improves intestinal flora imbalance, particularly in constipation-predominant irritable bowel syndrome (IBS). Constipation-predominant IBS leads to a decrease in butyrate-producing bacteria, reduced butyrate production capacity, impaired intestinal barrier function, increased permeability, and weakened intestinal motility, accompanied by pathogenic bacterial proliferation. After administration of Liu Mo Tang, the abundance of butyrate-producing bacteria is upregulated, and the increase of abnormal bacteria is inhibited, which helps restore intestinal butyrate supply, improves intestinal barrier function, and promotes the recovery of intestinal motility. By reshaping the balance between butyrate-producing bacteria and pro-inflammatory bacteria, it effectively improves intestinal flora imbalance in IBS.

The application provides application of Lactobacillus paracasei K56 in preparation of products for improving intestinal peristalsis and promoting defecation, and relates to the technical field of biotechnology. The application comprises application of Lactobacillus paracasei K56 in preparation of products containing at least one efficacy of improving small intestinal propulsion rate of a subject, promoting intestinal peristalsis of the subject and promoting defecation of the subject, wherein the products comprise a fermentation product fermented by using a fermenting agent containing Lactobacillus paracasei K56, and the fermentation substrate contains milk; and the application comprises increasing the proportion of the number of dead Lactobacillus paracasei K56 cells in the fermented product relative to the total number of Lactobacillus paracasei K56 cells. The application alleviates the technical problem that inactivation of bacteria in a fermented product causes the probiotic function to be affected.

The application provides a probiotic preparation and application thereof. The probiotic preparation comprises active ingredients and adjuvants, wherein the active ingredients comprise oxygen scavenging bacteria, organic acid producing bacteria and space-occupying bacteria; the oxygen scavenging bacteria are Weizmannia bacteria, the organic acid producing bacteria are lactobacillus or lactobacillus plantarum, and the space-occupying bacteria are bifidobacterium; the water activity of the probiotic preparation is less than or equal to 0.3, preferably 0.04-0.3, further preferably 0.04-0.2, and more preferably 0.04-0.15. The probiotic preparation has high live bacteria stability when stored at room temperature. Moreover, the probiotic preparation can effectively improve functional gastrointestinal diseases and has bidirectional regulation function, and is suitable for different intestinal motility disorders, such as diarrhea and constipation.

The present application belongs to the technical field of traditional Chinese medicine, and specifically discloses a traditional Chinese medicine composition for treating children's functional dyspepsia, a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw medicinal materials by weight: Fructus Aurantii Immaturus 5-20 parts, Magnolia officinalis 5-20 parts, Forsythia suspensa 5-30 parts, Dendrobium 5-30 parts, Atractylodes macrocephala 5-20 parts, and Glycyrrhiza 5-30 parts. The pharmacological experiment results show that the traditional Chinese medicine composition has the effects of improving gastrointestinal motility and regulating gastrointestinal hormone secretion, has a significant therapeutic effect on children's functional dyspepsia, has stable curative effect, and has a small dosage. Meanwhile, the present application has the advantages of simple process operation, low cost, good controllability and stability, and is suitable for industrialized mass production.

This invention discloses the application of Rehmannia glutinosa exosomes in the preparation of drugs for the prevention of colitis, belonging to the field of plant exosome technology. The Rehmannia glutinosa exosomes extracted using the specific process of this invention not only significantly reduced the DAI score of a colitis model to below 2.0 and restored TNF-α to normal levels, but also unexpectedly improved intestinal motility disorders associated with colitis by bidirectionally regulating gastrointestinal hormones (inhibiting VIP / ET-1 and promoting MTL / SP). This effect is significantly superior to that of traditional water and alcohol extracts of Rehmannia glutinosa.

The present application discloses a polysaccharide for preventing, treating or improving chronic constipation, and a preparation method and application thereof. The polysaccharide can improve or restore intestinal barrier integrity, increase the expression amount of colon tight junction proteins, regulate the proportion of intestinal microbe beneficial flora, increase the content of short-chain fatty acids, improve gastrointestinal motility, regulate intestinal oxidative stress, increase the fecal water content and intestinal transport rate of constipation subjects, reduce intestinal tissue damage, and the like, thereby being capable of being used for preventing, treating or improving chronic constipation. In addition, the polysaccharide has the advantages of high safety and good curative effect.

The application discloses a gastric electrical monitoring and evaluation method, comprising the following steps: determining a monitoring original signal and a lead signal corresponding to maximum power according to a power spectrum of a gastric electrical original signal; performing filtering processing to obtain a pretreated first signal and a pretreated second signal; determining amplitude phase information and artifact information according to the pretreated first signal and the pretreated second signal; determining a target analytical phase and a target gastric electrical signal according to the amplitude phase information, the pretreated second signal and the artifact information; determining a signal time-frequency domain index, a slow wave propagation direction and a gastric electrical slow wave phase coupling degree according to the target analytical phase and the target gastric electrical signal; and determining a gastrointestinal motility evaluation result according to the signal time-frequency domain index, the slow wave propagation direction and the gastric electrical slow wave phase coupling degree. The application further provides a gastric electrical monitoring and evaluation system. The application monitors from a time-frequency domain feature of a signal and a time-space feature of a stomach, obtains monitoring data for gastric evaluation, and improves the accuracy of gastric state evaluation.

This invention discloses a traditional Chinese medicine composition for regulating calcium ion homeostasis in the stomach, belonging to the field of traditional Chinese medicine technology. It is made from calcined oyster shell, calcined abalone shell, dried plum, poria cocos, and jujube seed in a specific weight ratio. This invention selects highly efficient calcium sources, calcined oyster shell and calcined abalone shell, in equal proportions, avoiding the deficiency of insufficient calcium content in traditional calcined dragon bone. It targets and supplements local calcium ions in the stomach, enhances the stabilizing effect of calcium ions on potassium ion channels, inhibits abnormal potassium ion leakage, and improves gastrointestinal smooth muscle tone. At the same time, it eliminates unsuitable medicinal materials such as Codonopsis pilosula, Astragalus membranaceus, Eucommia ulmoides, and Lycium barbarum. It uses Prunus mume to inhibit the proliferation of harmful bacteria in the small intestine and reduce fermentation and gas production, Poria cocos to supplement gastrointestinal trace elements, and Ziziphus jujuba var. spinosa to stabilize potassium ion channels, restore the calcium-potassium ion balance in the stomach, improve gastrointestinal motility rhythm, and alleviate problems such as small intestinal bacterial overgrowth, insufficient gastrointestinal motility, and abdominal distension. This composition does not contain sucrose, maltodextrin, chemical additives, or irritating excipients. It is fully decocted and suitable for people with fragile gastrointestinal barriers and immune sensitivity. The raw materials are safe and readily available, the preparation method is simple, and it has broad application prospects in gastrointestinal conditioning.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a pharmaceutical composition for treating simple obesity of spleen deficiency and dampness retention type and its application. This pharmaceutical composition is prepared based on seven traditional Chinese medicines listed in the Food and Drug Catalogue: Codonopsis pilosula, Poria cocos, Coix lacryma-jobi, Dioscorea opposita, Nelumbo nucifera, Lilium brownii, and Ziziphus jujuba. The pharmaceutical composition provided by this invention improves the condition of swollen, pale, and white-coated tongue in rats with simple obesity of spleen deficiency and dampness retention type, and improves abnormal lipid metabolism; it can effectively regulate abnormalities in serum BUN, UA, MTL, VIP, and other indicators in rats with simple obesity of spleen deficiency and dampness retention type, improve gastrointestinal emptying, enhance gastrointestinal motility, and increase the calcium content of myocardial cell membranes. 2+ -ATPase, Na + -K + - It increases ATPase activity, improves cellular energy metabolism, and reduces the risk of cardiovascular disease caused by obesity; it inhibits the expression levels of BUN and UA, which can treat obesity-induced hyperuricemia and improve renal metabolism. It also exerts a therapeutic effect on simple obese rats with spleen deficiency and dampness retention.

This invention provides a *Hydroxystoma coagulans* strain and its uses. This *Hydroxystoma coagulans* strain was deposited on November 3, 2025, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 36494. The *Hydroxystoma coagulans* strain provided by this invention has multiple functions: it can enhance whole intestinal motility, accelerating small intestinal propulsion and promoting colonic emptying; it can soften stool, significantly increasing stool water content, thus fundamentally improving constipation.

The present application provides a probiotic preparation and its use. The probiotic preparation of the present application comprises active ingredients and adjuvants, wherein the active ingredients comprise oxygen scavengers, organic acid producers and place holders; the adjuvants comprise flavoring agents, oligosaccharides and other additives; wherein the oligosaccharides are not lactulose, stachyose, raffinose, oligogentiobiose and oligochitosan, and the other additives are not theaflavins, ethylenediaminetetraacetic acid disodium salt and sorbic acid. The present application effectively promotes the metabolic activity of probiotics through a specific combination of adjuvants, rather than just providing physical protection or nutritional support. Experimental data show that the adjuvant combination of the present application can significantly and continuously improve the oxidation-reduction potential and Na + K + ATPase activity of probiotics. Moreover, the probiotic preparation of the present application can effectively improve functional gastrointestinal diseases and has a bidirectional regulation function, which is suitable for different intestinal motility disorders, such as diarrhea and constipation.

The application discloses a kind of pelvic fracture postoperative intestinal function recovery methods based on multi-modal evaluation, it is related to medical postoperative rehabilitation evaluation technical field, including collecting patient postoperative gastrointestinal motility related physiological indexes, pelvic cavity imaging data, clinical manifestation text record and so on multi-modal data, pre-processing is extracted multi-modal evaluation characteristics;Characteristics are input into coevolution network, each evaluation branch parallel processing corresponding modal characteristics, through shared intermediate representation layer completes feature exchange and weight mutual adjustment, combined with the adaptive contribution degree of branch exchange after intermediate representation and own state vector calculation, weighted fusion obtains comprehensive intestinal function recovery state score, compares threshold value and determines recovery stage and matches output rehabilitation intervention suggestion.The method can realize the linkage processing of multi-modal characteristics, dynamically adapt each modal evaluation weight, improve the accuracy of intestinal function recovery evaluation, output and patient recovery stage adapt to rehabilitation intervention scheme.

An orally swallowable, immediate release tablet, comprising itopride or a pharmaceutically acceptable salt thereof as an active ingredient, characterized in that the tablet comprises granules containing the active ingredient, mannitol and optionally at least one additional pharmaceutically acceptable excipient, wherein the tablet does not contain lactose. Said tablet for use in prevention or treatment of gastrointestinal motility disorders. A method for manufacturing the orally swallowable, immediate release tablet according to any of the preceding claims, comprising: a) granulating itopride or a pharmaceutically acceptable salt thereof with mannitol and optionally at least one additional pharmaceutically acceptable excipient, b) optionally blending the granules obtained in step a) with at least one extra-granular pharmaceutically acceptable excipient, and c) compressing the granules from step a) or the blend from step b) into tablets.

This invention relates to the field of microbial technology and discloses a strain of *Lactobacillus fermentans* and its applications. The preservation number of the *Lactobacillus fermentans* is CGMCC No. 37245. This strain exhibits excellent antibacterial ability, effectively inhibiting intestinal pathogens; it has a strong ability to degrade dietary fiber or indigestible sugars (such as fructooligosaccharides, β-glucan, galactooligosaccharides, etc.) and can effectively proliferate in the intestinal environment; the *Lactobacillus fermentans* CGMCC No. 37245 of this invention produces a high yield of hydrogen peroxide during fermentation, making this strain potentially useful in preventing antibiotic-associated diarrhea and traveler's diarrhea; furthermore, the *Lactobacillus fermentans* CGMCC No. 37245 of this invention can relieve both constipation and diarrhea, demonstrating a bidirectional regulatory function on intestinal motility.